Chugai Pharmaceutical Co., Ltd: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Chugai's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for Chugai over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Chugai's performance against key rivals in the prescription pharmaceutical sector* Assess the strong sales performance of the company's monoclonal antibody (MAb) franchise, positioning Chugai as the leading Japanese MAb player

[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Chugai: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
Chugai dominates the Japanese MAb landscape
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest prescription pharma product news
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Consolidation into the Roche group in October 2002
Divestments since the Roche merger have promoted prescription pharmaceuticals focus
Current corporate structure
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2008–14
KEY PRODUCTS AND COMPETITORS
Key findings
Overview
Oncology
[Missing title]
Herceptin
Rituxan
Neutrogin
Tarceva
Hematology
Epogin
R-744/Mircera
Immunology & inflammation
[Missing title]
Infectious disease
Tamiflu
Pegasys
Genitourinary
Evista
APPENDIX
References
Abbreviations
Exchange rates

[Inhaltsverzeichnis ausblenden]